Strategic Global Advisors LLC bought a new stake in HCA Healthcare Inc (NYSE:HCA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,208 shares of the company’s stock, valued at approximately $298,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HCA. Steward Partners Investment Advisory LLC lifted its stake in shares of HCA Healthcare by 2.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 3,940 shares of the company’s stock worth $532,000 after buying an additional 82 shares in the last quarter. Cornerstone Advisors Inc. increased its holdings in shares of HCA Healthcare by 15.0% in the second quarter. Cornerstone Advisors Inc. now owns 675 shares of the company’s stock valued at $91,000 after purchasing an additional 88 shares during the last quarter. Commonwealth Bank of Australia lifted its position in HCA Healthcare by 3.6% during the first quarter. Commonwealth Bank of Australia now owns 2,883 shares of the company’s stock worth $374,000 after buying an additional 100 shares in the last quarter. Signaturefd LLC lifted its position in HCA Healthcare by 7.1% during the first quarter. Signaturefd LLC now owns 1,863 shares of the company’s stock worth $243,000 after buying an additional 123 shares in the last quarter. Finally, AE Wealth Management LLC boosted its stake in HCA Healthcare by 0.7% during the second quarter. AE Wealth Management LLC now owns 18,115 shares of the company’s stock worth $2,449,000 after buying an additional 126 shares during the last quarter. Institutional investors and hedge funds own 70.38% of the company’s stock.
NYSE:HCA traded up $0.84 during midday trading on Wednesday, reaching $130.94. The company had a trading volume of 1,073,310 shares, compared to its average volume of 1,353,669. The firm has a market capitalization of $43.48 billion, a price-to-earnings ratio of 13.40, a PEG ratio of 1.09 and a beta of 0.87. The stock’s fifty day simple moving average is $127.10 and its 200-day simple moving average is $129.27. HCA Healthcare Inc has a 12-month low of $110.31 and a 12-month high of $147.42.
HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $2.21 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.49 by ($0.28). The company had revenue of $12.60 billion for the quarter, compared to analysts’ expectations of $12.61 billion. HCA Healthcare had a negative return on equity of 135.90% and a net margin of 7.46%. HCA Healthcare’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 EPS. As a group, equities research analysts predict that HCA Healthcare Inc will post 10.4 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Tuesday, September 3rd will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date of this dividend is Friday, August 30th. HCA Healthcare’s dividend payout ratio is presently 16.38%.
HCA has been the topic of several analyst reports. UBS Group lifted their price target on HCA Healthcare from $172.00 to $181.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Stephens set a $150.00 price objective on HCA Healthcare and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research cut HCA Healthcare from a “buy” rating to a “hold” rating and set a $130.00 target price for the company. in a research note on Monday, May 27th. Mizuho set a $153.00 target price on HCA Healthcare and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, Bank of America raised HCA Healthcare from an “underperform” rating to a “neutral” rating and upped their price target for the company from $130.00 to $137.00 in a research note on Friday, September 6th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $155.29.
In other news, SVP Kathleen M. Whalen sold 977 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $127.56, for a total transaction of $124,626.12. Following the completion of the transaction, the senior vice president now directly owns 11,484 shares of the company’s stock, valued at approximately $1,464,899.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Patricia F. Elcan bought 250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were acquired at an average cost of $124.10 per share, for a total transaction of $31,025.00. The disclosure for this purchase can be found here. Insiders own 2.70% of the company’s stock.
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Read More: Trading signals using Bollinger bands
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare Inc (NYSE:HCA).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.